BioTech

Biogen To Acquire Apellis

March 31, 2026 — 07:21 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Biogen Inc. (BIIB) and Apellis Pharmaceuticals (APLS) announced they have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.

The acquisition is expected to be increasingly accretive to Biogen's Non-GAAP EPS starting in 2027. The transaction is expected to meaningfully increase Biogen's non-GAAP EPS compounded annual growth rate through the end of the decade.

In pre-market trading on NasdaqGS, Apellis shares are up 140.5 percent to $41.10.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Biogen To Acquire Apellis

Tags

Latest Articles